Compare Cassava Sciences Inc (FLNA) vs KeyCorp (KEY) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

KeyCorp (KEY) trades at $19.83, down 1.54% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent management appointments and a 2026 revenue outlook raise to 8% growth signal operational momentum. However, technical indicators show oversold conditions with RSI at 26.31 and bearish moving average signals.

KEY presents a value opportunity with attractive valuation metrics and consistent earnings performance. The 26% upside to consensus price target of $25.00 and 60.79% analyst buy rating support bullish sentiment. Risks include frozen dividend payments since 2023 and sensitivity to interest rate changes. The bank's aggressive share buyback program and improving net interest income provide catalysts for potential appreciation.